.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Covington
Medtronic
Colorcon
Chinese Patent Office
Merck
Federal Trade Commission
Teva
Deloitte
Cantor Fitzgerald

Generated: September 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Medicaments
Abstract:Pharmaceutical compositions comprising effective amounts of salmeterol (and a physiologically acceptable salt thereof) and fluctuations propionate as a combined preparation for simultaneous, sequential or separate administration by inhalation in the treatment of respiratory disorders.
Inventor(s): Palmer; James B. D. (Princeton, NJ)
Assignee: Glaxo Group Limited (Greenford, GB)
Application Number:10/933,483
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

No matches for this query

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8920392Sep 08, 1989
United Kingdom8923644Oct 20, 1989

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom9019659► Subscribe
France2651677► Subscribe
Switzerland680983► Subscribe
Cyprus1817► Subscribe
Germany19975040► Subscribe
Germany69005951► Subscribe
Denmark0416951► Subscribe
European Patent Office0416951► SubscribeC990012Netherlands► Subscribe
European Patent Office0416951► Subscribe12/1999Austria► Subscribe
Spain2062392► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Cerilliant
McKinsey
Medtronic
Daiichi Sankyo
Cantor Fitzgerald
Cipla
Moodys
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot